Adoptive transfer of receptor-engineered T cells has produced impressive results in treating
patients with B cell leukemias and lymphomas. This success has captured public …

Summary On July 1, 2014, the United States Food and Drug Administration granted
'breakthrough therapy'designation to CTL 019, the anti‐CD 19 chimeric antigen receptor T …

Many tumors overexpress tumor-associated antigens relative to normal tissue, such as
EGFR. This limits targeting by human T cells modified to express chimeric antigen receptors …

Performance enhancement of the immune system can now be generated through ex vivo
gene modification of T cells in order to redirect native specificity to target tumor antigens …

Artificial antigen presenting cells (aAPCs) with surface‐anchored T cell activating ligands
hold great potential in adoptive immunotherapy. However, it remains challenging to …

γδ T cells hold promise for adoptive immunotherapy because of their reactivity to bacteria,
viruses, and tumors. However, these cells represent a small fraction (1–5%) of the peripheral …

T cells can be reprogrammed to redirect specificity to tumor-associated antigens (TAAs)
through the enforced expression of chimeric antigen receptors (CARs). The prototypical …

Microfluidic intracellular delivery approaches based on plasma membrane poration have
shown promise for addressing the limitations of conventional cellular engineering …

CAR T-cell therapeutic optimization, including intrinsic and extrinsic factors, is critical to
developing effective CAR T-cell therapies for cancer. The excitement of CAR T-cell …

Adoptive transfer of autologous ex vivo expanded tumor-infiltrating lymphocytes (TIL) is a
highly successful cell therapy approach in the treatment of late-stage melanoma …